Am. J. Respir. Crit. Care Med., Volume 165, Number 7, April 2002, 922-926

Acute Effects of Aerosolized S-Nitrosoglutathione in Cystic Fibrosis

Ashley H. Snyder, Marianne E. McPherson, John F. Hunt, Michael Johnson, Jonathan S. Stamler, and Benjamin Gaston

Division of Pediatric Respiratory Medicine, University of Virginia School of Medicine and Department of Chemistry, University of Virginia, Charlottesville, Virginia; and Departments of Medicine and Biochemistry, Howard Hughes Medical Institute, Duke University School of Medicine, Durham, North Carolina

S-Nitrosoglutathione (GSNO), a naturally occurring constituent of airway lining fluid, enhances ciliary motility, relaxes airway smooth muscle, inhibits airway epithelial amiloride-sensitive sodium transport, and prevents pathogen replication. Remarkably, airway levels of GSNO are low in patients with cystic fibrosis (CF). We hypothesized that replacement of airway GSNO would improve gas exchange in CF. In a double-blind, placebo controlled study, we administered 0.05 ml/kg of 10 mM GSNO or phosphate buffered saline by aerosol to patients with CF and followed oxygen saturation, spirometry, respiratory rate, blood pressure, heart rate, and expired nitric oxide (NO). Nine patients received GSNO and 11 placebo. GSNO inhalation was associated with a modest but sustained increase in oxygen saturation at all time points. Expired NO increased in the low ppb range with GSNO treatment, peaking at 5 minutes but remaining above baseline at 30 minutes. There were no adverse effects. We conclude that GSNO is well tolerated in patients with CF and improves oxygenation through a mechanism that may be independent of free NO. Further, GSNO breakdown increases expired NO. We suggest that therapy aimed at restoring endogenous GSNO levels in the CF airway may merit study.

This article has been cited by other articles:

				S. J. Lewis and B. Gaston S-Nitrosothiol Deficiency in Asthma Am. J. Respir. Crit. Care Med., August 1, 2009; 180(3): 198 - 199. [Full Text] [PDF]

				C. M. Thompson, B. Sonawane, and R. C. Grafstrom The Ontogeny, Distribution, and Regulation of Alcohol Dehydrogenase 3: Implications for Pulmonary Physiology Drug Metab. Dispos., August 1, 2009; 37(8): 1565 - 1571. [Abstract] [Full Text] [PDF]

				O. M. Granillo, M. V. Brahmajothi, S. Li, A. R. Whorton, S. N. Mason, T. J. McMahon, and R. L. Auten Pulmonary alveolar epithelial uptake of S-nitrosothiols is regulated by L-type amino acid transporter Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L38 - L43. [Abstract] [Full Text] [PDF]

				J. Prousky The Treatment of Pulmonary Diseases and Respiratory-Related Conditions with Inhaled (Nebulized or Aerosolized) Glutathione Evid. Based Complement. Altern. Med., March 1, 2008; 5(1): 27 - 35. [Abstract] [Full Text] [PDF]

				K. Zaman, S. Carraro, J. Doherty, E. M. Henderson, E. Lendermon, L. Liu, G. Verghese, M. Zigler, M. Ross, E. Park, et al. S-Nitrosylating Agents: A Novel Class of Compounds That Increase Cystic Fibrosis Transmembrane Conductance Regulator Expression and Maturation in Epithelial Cells Mol. Pharmacol., October 1, 2006; 70(4): 1435 - 1442. [Abstract] [Full Text] [PDF]

				H. Grasemann, F. Kurtz, and F. Ratjen Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212. [Abstract] [Full Text] [PDF]

				B. Gaston, D. Singel, A. Doctor, and J. S. Stamler S-Nitrosothiol Signaling in Respiratory Biology Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1186 - 1193. [Abstract] [Full Text] [PDF]

				K. Zaman, M. H. Hanigan, A. Smith, J. Vaughan, T. Macdonald, D. R. Jones, J. F. Hunt, and B. Gaston Endogenous S-Nitrosoglutathione Modifies 5-Lipoxygenase Expression in Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., April 1, 2006; 34(4): 387 - 393. [Abstract] [Full Text] [PDF]

				ATS Workshop Proceedings: Exhaled Nitric Oxide and Nitric Oxide Oxidative Metabolism in Exhaled Breath Condensate. Proceedings of the ATS, January 1, 2006; 3(2): 131 - 145. [Full Text] [PDF]

				L. G. Que, L. Liu, Y. Yan, G. S. Whitehead, S. H. Gavett, D. A. Schwartz, and J. S. Stamler Protection from Experimental Asthma by an Endogenous Bronchodilator Science, June 10, 2005; 308(5728): 1618 - 1621. [Abstract] [Full Text] [PDF]

				A. M. Firoved, S. R. Wood, W. Ornatowski, V. Deretic, and G. S. Timmins Microarray Analysis and Functional Characterization of the Nitrosative Stress Response in Nonmucoid and Mucoid Pseudomonas aeruginosa J. Bacteriol., June 15, 2004; 186(12): 4046 - 4050. [Abstract] [Full Text] [PDF]

				C. H. Goss, S. A. Newsom, J. S. Schildcrout, L. Sheppard, and J. D. Kaufman Effect of Ambient Air Pollution on Pulmonary Exacerbations and Lung Function in Cystic Fibrosis Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 816 - 821. [Abstract] [Full Text] [PDF]

				S. C. George, M. Hogman, S. Permutt, and P. E. Silkoff Modeling pulmonary nitric oxide exchange J Appl Physiol, March 1, 2004; 96(3): 831 - 839. [Abstract] [Full Text] [PDF]

				H.-W. Shin, C. M. Rose-Gottron, D. M. Cooper, R. L. Newcomb, and S. C. George Airway diffusing capacity of nitric oxide and steroid therapy in asthma J Appl Physiol, January 1, 2004; 96(1): 65 - 75. [Abstract] [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				M. Howard, H. Fischer, J. Roux, B. C. Santos, S. R. Gullans, P. H. Yancey, and W. J. Welch Mammalian Osmolytes and S-Nitrosoglutathione Promote {Delta}F508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein Maturation and Function J. Biol. Chem., September 12, 2003; 278(37): 35159 - 35167. [Abstract] [Full Text] [PDF]

				M. J. Tobin Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 333 - 344. [Full Text] [PDF]